key: cord-0998133-5lj17odo
authors: Durant, T. J.; Koch, C. D.; Kerantzas, C. A.; Peaper, D. R.
title: Performance Decay of Molecular Assays Near the Limit of Detection: Probabilistic Modeling using Real-World COVID-19 Data
date: 2021-04-27
journal: nan
DOI: 10.1101/2021.04.26.21254638
sha: ee085d2161d1f5ac01a44119c2490da9bdda4616
doc_id: 998133
cord_uid: 5lj17odo

The gold standard for diagnosis of COVID-19 is detection of SARS-CoV-2 RNA by RT-PCR. However, the effect of systematic changes in specimen viral burden on the overall assay performance is not quantitatively described. We observed decreased viral burdens in our testing population as the pandemic progressed, with median sample Ct values increasing from 22.7 to 32.8 from weeks 14 and 20, respectively. We developed a method using computer simulations to quantify the implications of variable SARS-CoV-2 viral burden on observed assay performance. We found that overall decreasing viral burden can have profound effects on assay detection rates. When real-world Ct values were used as source data in a bootstrap resampling simulation, the sensitivity of the same hypothetical assay decreased from 97.59 (95% CI 97.3-97.9) in week 12, to 74.42 (95% CI 73.9-75) in week 20. Furthermore, simulated assays with a 3-fold or 10-fold reduced sensitivity would both appear to be >95% sensitive early in the pandemic, but sensitivity would fall to 85.55 (95% CI 84.9-86.2) and 74.38 (95% CI 73.6-75.1) later in the pandemic, respectively. Our modeling approach can be used to better quantitate the impact that specimen viral burden may have on the clinical application of tests and specimens.

On February 4, 2020, the U.S. Department of Health and Human Services (HHS) declared a public health 54 emergency and authorized the emergency use of in vitro diagnostics (IVD) for the detection of the 55 severe acute respiratory coronavirus 2 (SARS-CoV-2). Since this time, the number of emergency use 56 authorizations (EUA) issued by the FDA, and the number of NAATs available for clinical use, have 57 increased linearly. Currently, the required data for EUA are primarily those which describe the analytic 58 sensitivity and specificity, and among available assays, these performance metrics are generally well 59 described. The FDA only recently released (https://bit.ly/2RUL3R2) results of testing using a standardized 60 panel of contrived viral samples, and a group recently compared assay limits of detection (LOD) using a 61 quantitated set of viral standards.(1) Finally, there have been several method to method comparisons of 62 SARS-CoV-2 testing. (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) However, at the time of this writing, the clinical performance of real-time 63 reverse transcription-PCR (RT-PCR) based assays remains a difficult metric to evaluate. 64

The preferred method for a laboratory diagnosis of acute COVID-19 is an amplified RNA test, 65 and RT-PCR is the most commonly used method. Among published reports of suspected clinical 66 inaccuracies observed with SARS-CoV-2 RT-PCR, both false positive and false negative results have been 67 reported. False positive results can occur due to specimen contamination, but analytical false positives 68 have been reported to the FDA. Much more concern has been focused on falsely negative results driven 69 by variation in test sensitivity. There are many variables in the testing process which arguably influence 70 key component of overall test performance, both in the analytic and clinical aspects of assay 77 consideration. 78

The diagnostic sensitivity of a test method is thought to be fairly constant across time, but 79 publications evaluating the performance of different COVID-19 diagnostic assays have demonstrated 80 highly variable sensitivity even for commercial assays with constant procedures. Additionally, studies of 81 different specimen types with potentially different viral burdens have not been consistent in their 82 reported sensitivity. (15) (16) (17) (18) This has profound implications for clinical decision making since different 83 levels of assay sensitivity encompassing specimen, collector, and assay may be required for different 84 clinical scenarios. 85

As of December 2020, there is no commonly available and recognized reference material for 86 population may influence the diagnostic performance of an assay. In a recent study by Green et al., Ct 100 values reported from samples where SARS-CoV-2 RNA was detected and stratified by patients who 101 received repeat testing versus a single test. Testing was performed on the Cobas 6800 assay, and 102 between single and repeat testing cohorts, they observed 3.38 and 6.59% increases in Ct values for gene 103 targets 1 and 2, respectively.(10) Accordingly, the authors note that this difference in viral burden can 104 influence the clinical sensitivity of the assay. While there are emerging reports which discuss the effect 105 of variable viral burden in samples with respect to patient-level diagnosis, the degree to which shifting 106

Ct values may influence the diagnostic sensitivity has not been quantitatively described. 107

During the initial weeks of the pandemic, we observed increasing rates of false negative results 108

during validation experiments at our institution. Upon investigation we noted higher Ct values among 109 the false negative samples. While it is known that higher Ct values are less likely to be detected, there 110 was a higher proportion of low viral burden specimens in our sample cohort relative to the beginning of 111 the pandemic. Given the potential impact of viral burden on test positivity, we sought to quantitate the 112 systematic distribution of Ct values in the tested population from our institution across epidemiologic 113 weeks. Further, because it was not practical to do multiple comparisons across multiple platforms to 114 reliably describe differences in assay performance due to changes in sample viral burden, we employed 115 mathematical modeling to quantitatively describe this. To this end, we used publicly available data to 116 develop a model of test performance characteristics corresponding to different viral burdens allowing 117 probabilistic-based simulation of RNA detection for a hypothetical COVID-19 assay evaluated at different 118 timepoints during the pandemic. We then developed a computational model to simulate the 119 assessment of RT-PCR clinical performance at our institution, using a bootstrap resampling method to 120 describe variations in test sensitivity based upon different underlying assay performance assumptions. 121

We hypothesize that mathematical modeling will demonstrate a temporal decay in diagnostic sensitivity 122 as viral burden in clinical samples decreased. 123 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Emergency Use Authorization by the US FDA, and has been previously described.

(2) The preferred 136 specimen type across all platforms was a NPS collected in 3 mL of universal or viral transport medium 137 (VTM), but other specimen types and collection methods were used as needed based upon supply and 138 reagent availability. 139 140

Retrospective laboratory test order and result data were extracted from our electronic health record 142

(EHR) and laboratory information system (LIS). Row-level data, indexed by container ID, included test 143 result interpretation (e.g., 'detected', 'not detected', etc.), Ct value, test method, and a collection 144 datetime stamp. Additional metadata included patient class (e.g., inpatient, outpatient, or emergency 145 department) at the time of their encounter, specimen collection type, and the resulting laboratory. 146 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 Custom scripts for data processing and analysis were implemented in Python (version 3.7.4), and R 147 (version 4.0.2). Linear regression of Ct values associated with each gene target was performed in 148

GraphPad Prism (version 8.4 .2) (GraphPad Software; San Diego, CA, USA). Ct value analysis was limited 149 to the platforms which provide a Ct value for each gene target which included the modified CDC assay 150 and the Xpert assay. Tests which were performed at reference laboratories -i.e., 'send-out' tests -were 151 not included in the Ct value analysis. CDC epidemiologic week numbers are used throughout the entirety 152 of this report. 153

Standardized assay performance analysis 155

Instructions for use (IFU) available on the US FDA website were reviewed on August 13, 2020. Limit of 156 detection performance data were extracted from IFU if they met the following criteria: 1) The test was 157 commercially available, 2) the test was an extracted RT-PCR assay, 3) at least 20 samples were tested at 158 each concentration. Four assays met these criteria: Roche Cobas SARS-CoV-2, Abbott Alinity m SARS-159

CoV-2 (Abbott Molecular Inc; Des Plaines, IL), Cepheid Xpert Xpress SARS-CoV-2, and Perkin Elmer New 160

Coronavirus Nucleic Acid Detection Kit (Perkin Elmer; Waltham, MA). The LOD, concentration tested, 161 number of samples tested, and number of samples detected were recorded for each assay. The data 162 from the Roche and Perkin Elmer assays were presented by RT-PCR target, while the data for the Abbott 163 and Cepheid assays were presented for the total assay. For the purposes of calculations and curve 164 fitting, the LOD of the Cepheid assay was changed to 0.005 PFU/mL from the claimed LOD of 0.02 165 PFU/mL since 95% of samples tested were positive at 0.005 PFU/mL. This revised LOD was consistent 166 with probit analysis determined LOD (Data Not Shown). To control for different LODs and units of 167 measure, each concentration tested was converted to a %-LOD. Individual samples with %-LOD greater 168 than 250% were excluded from further analysis. The %-Detected was calculated for each assay or gene 169 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21254638 doi: medRxiv preprint target. The %-Detected was plotted versus the %-LOD, and non-linear regression analysis with an 170 exponential plateau function (where; Y min = 0 and Y max = 100) was fit in GraphPad Prism. Additionally, the 171 fraction detected was used to determine a probit value, probit versus Log(10) %-LOD was plotted, and 172 linear regression was performed (GraphPad Prism v8). 173

The purpose of the model simulation was to determine -for a given cohort of positive samples -what 176 fraction would be detected given the viral burden in the sample, and across the tested cohort, what is 177 the calculated sensitivity. To this end, a function to calculate the probability of detection, on a per 178 sample basis, was extrapolated from the non-linear regression model of the IFU data described above. 179

Clinical performance of a hypothetical test was first simulated using Ct values from the modified CDC 180 assay, pertaining to the N2 gene target. All N2 Ct values across the observational period, which were 181 derived from a sample that was clinically reported as 'detected', were collected from the LIS ( Figure 1A ). 182

These were subsequently collated into arrays and separated into groups by epidemiologic week (Figure  183 1B). From each dataset, corresponding to an epidemiology week, individual samples and their 184 corresponding Ct value were randomly selected using a bootstrap resampling method with replacement 185 ( Figure 1C ).(19) The Ct value was then used as input for the probability function (P) ( Figure 1D ). The Ct 186 value at the LOD (Ct LOD ) for the hypothetical assay for this simulation was defined as the viral 187 concentration corresponding to N2 Ct LOD = 35.0. Equation P yields a sum-to-one probability of 'detected' 188 or 'not detected', wherein the probability was then used as input for a single binomial distribution 189 function to return N (e.g., where a high P would be likely to return N = 1 (i.e., 'Detected') and a low P 190 would be likely to return N = 0 (i.e., 'Not detected')) ( Figure 1E ). Output N was then compared with the 191 ground truth (i.e., the clinical test result), which in this case was always 'detected', to determine if the 192 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The observation period for this project was between March 15, 2020 and July 31, 2020 (corresponding 208 to epidemiologic weeks 12 through 31). The flagship hospital for our HDO is located in New Haven, CT, 209 and we were part of the "first wave" of COVID-19 infections in the USA. We implemented testing locally 210 on March 13, 2020, with the first full week of testing occurring on week 12. COVID-19 positivity rates by 211 PCR testing peaked at week 14 (approx. 30%). This peak has been followed by a long tail of reduced 212 positivity in the setting of dramatically increased outpatient testing. Testing of inpatients and those in 213 the ED has remained stable since early in the pandemic (Figure 2) . 214 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 )(Supplemental Figure 2) . 228 229

We wished to determine the quantitative effect of rising Ct values on diagnostic test performance, but 231

Ct values are not transmutable among assays. Quantitative viral burden measurements would facilitate 232 comparisons among assays, but these are not widely done, and assay limits of detection can be 233 measured in a variety of units that cannot be interconverted. We hypothesized that most extracted RT-234 PCR assays would have similar behavior at and below the LoD. Additionally, we wished to derive a 235 method wherein the probability of a single sample being reported as positive could be calculated based 236 upon its Ct value compared to the Ct LoD . 237 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We reviewed instructions for use available on the FDA website for commercially available, 238 extracted real-time RT-PCR assays for COVID-19. Data from assays that contained detailed LOD studies, 239 as described in the materials and methods, were extracted, and four assays (Abbott Alinity m, Perkin 240

Elmer, Roche cobas, and Xpert Xpress) met these criteria with individual gene targets from two assays (N 241 and ORF1ab from Perkin Elmer and Target 1 and Target 2 from Roche cobas) being used. Tested 242 concentrations were converted to %-LOD to normalize across testing platforms and units of measure. 243

Plotting %-detected v. %-LoD allowed us to fit an exponential plateau curve (Figure 4) Ct sample to Ct LoD , we simulated the performance of a single hypothetical assay as observed viral burden 256 among positive samples decreased as the pandemic progressed as summarized in Figure 1 . Assuming a 257 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21254638 doi: medRxiv preprint relationship between LoD and Ct value is consistent within a given sample, samples with Ct values at the 258 assay LoD should be detected 95% of the time, and samples with Ct values above the Ct LoD should have a 259 non-zero probability of detection that is inversely related to Ct sample (i.e., samples with Ct sample > Ct LoD may 260 be detected, but less than 95% of the time). Accordingly, for the simulated test performance of a 261 hypothetical assay with a Ct LoD corresponding to N2 Ct = 35 in the CDC assay, the simulated diagnostic 262 sensitivity decreased from 97.59 (95% CI 97.3 to 97.9) in week 12, to 74.42 (95% CI 73.9 to 75) in week 263 20. In addition, the coefficient of variation (CV) increased from 1.6% to 3.6% from week 12 to week 20, 264 respectively. At week 16, the simulated diagnostic sensitivity fell below 95% with an average of 94.17 265 (95% CI 94 to 94.4) ( Figure 5) . 266

The second iteration of simulated test performance was carried out using Ct values of the N2 267 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Table 1 and Supplemental Figure 2 ), did not 291 change significantly over the course of the 2019 to 2020 flu-season (slope: 0.063 (95% CI -0.02 to 0.23)). 292

We hypothesize that there are two primary reasons for the observed shift in SARS-CoV-2 gene target Ct 293 values: 1) repeat testing of known positive patients later in disease when viral shedding is lower and 2) 294 shifting of testing guidelines to test more patients with less severe symptoms. Repeat testing cannot 295 explain all these changes, as GeneXpert testing at our institution is predominantly performed on newly 296 admitted patients. Indeed, this observation likely warrants further investigation as to the underlying 297 etiology and pathogenesis of SARS-CoV-2. The primary focus of this report, however, was to develop a 298 method to quantitatively describe the effect this observation may have on the diagnostic sensitivity an 299 assay. 300 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 The LoD is defined as the concentration at which there is a 95% probability of amplification and 301 detection of target nucleic acid. The second edition of the Clinical and Laboratory Standards Institute 302 (CLSI) guideline EP17-A2 recommends probit analysis, a parametric statistical method for estimating the 303 LoD based on observed detection rates and concomitant nucleic acid concentration data, but probit 304 analysis would not allow us to back calculate discrete probabilities of detection each specimen. (21) 305 Nonetheless, a probit regression was used to model the IFU LoD data which provided a good fit, with an 306 R squared of 0.8767 (Supplemental Figure 1) . Instead, we used an exponential method to fit publicly 307

available LoD data to model the probability of detection for Ct values in our dataset. This allowed more 308 flexibility by treating Ct values as continuous input variables for the test performance simulation which 309 could be used to calculate a sum-to-one probability of detection using equation (A). In addition, the non-310 linear regression resulted in a slightly more optimal R squared value of 0.9128. 311

We assumed for our model that a 10-fold change in virus concentration would result in a shift of 312 3.32 cycles across the entire analytical range. While this has been demonstrated for high viral burdens, 313 samples with lower viral burdens near the LoD may not predictably behave in this manner. We also 314 assumed that our baseline tests (e.g. LDT modified CDC assay and Xpert Xpress) were highly sensitive. 315

Our internal comparisons among assays is consistent with this assumption, but more complex 316 assumptions and/or models would be needed to extrapolate the performance of a more sensitive 317 method from the data generated by a less sensitive method. Finally, we did not incorporate test 318 specificity and potential false-positive results into our models. While this could be accomplished through 319 assigning a probability of detection to negative specimens corresponding to a pre-determined false 320 positive rate, it would not have a comparable set of data as that available for test sensitivity. 321

While our analysis was performed on NP swabs, our modeling data has implications for different 322 viral burdens associated with different specimen types. For example, if viral burdens are 5-to 10-fold 323 lower in alternative specimens compared to NP swabs, then the overall clinical sensitivity of the same 324 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101/2021.04.26.21254638 doi: medRxiv preprint assay would be expected to vary according to our model. Variations in viral burden with time would 325 compound this change in performance, as well. Indeed, the modeling data presented in this report 326 demonstrate how the rate of detection can vary significantly as the distribution of viral burden changes 327 among samples tested, and this may explain the highly variable performance seen for some sample 328 types such as nasal swabs and saliva. (17, 23) 329 In order to interpret the effects of samples with lower viral burdens on test performance 330 characteristics in publications, whether in comparisons between methods or sample types, rigorous 331 reporting of study parameters as detailed in the STARD 2015 guidelines is necessary.(24) Moreover, 332 compared to other studies of viral diagnostics, it is even more important for COVID studies to detail the 333 provenance of the specimens used including dates of sample collection, explicit case-finding criteria, and 334 local positivity rates. Currently, the literature predominantly reports on samples collected in late March 335 to early May, when testing of asymptomatic patients was not as prevalent.(2, 3, 25) As the publication 336 cycle progresses and studies from later months emerge, it will be important to observe for greater 337 variation in performance characteristics as predicted by and demonstrated in this report. The Ct values 338 of patient specimens are important data to contextualize study findings. However, Ct ranges alone are 339 not sufficient due to the stochastic nature of detection near the LoD, and the proportion of specimens 340 with a low viral burden as evidenced by higher Ct values is an important metric rather than simply the 341 maximum observed Ct.(7) Subsequently, concordance and/or percent-positive-agreement analysis 342 should be tied to ranges of Ct values from well-studied assays in order to properly assess assay 343 performance on different patient populations. Broadly, these parameters will help guide the 344 interpretation and applicability of study results for different institutions and potentially different clinical 345 use case scenarios. 346

More fundamentally, variation in assay performance over time may be partly attributable to 347 changes in case definition. Whereas early in the pandemic case definitions included clinical criteria when 348 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 27, 2021. ; https://doi.org/10.1101 https://doi.org/10. /2021 testing was more restricted, widespread testing of asymptomatic patients has led to laboratory test-349 based case definitions. In lieu of a definitive diagnostic gold standard, high sensitivity methods have 350 been used either individually or with other high sensitivity methods as part of a composite reference 351 standard. Importantly, a single result arising from the use of only one high-sensitivity method as a 352 reference standard may be limited by the stochastic nature of test performance near the LoD. Multi-353 target assays are likely to be less susceptible to stochastic effects than single-target assays, but also 354 introduce the need for studies to precisely define how each target result is translated into an overall 355 positive or negative specimen result. Though marked discordance between high sensitivity methods at 356

high Ct values has not been observed in several studies, discordance may emerge in data from later 357 months in the pandemic.(2, 3, 7) These considerations again highlight the need to evaluate high 358 sensitivity methods over time, individually and together, in order to capture variations in diagnostic 359 sensitivity. 360

Laboratory testing, particularly molecular-based assays, are often thought of being deterministic 361 in nature when generating a result -i.e., if the RNA is present, it will be detected. Accordingly, if the test 362 methodology is deterministic and stationary, we often think of test performance as stationary. However, 363 as viral burden in the sample approaches the LoD, it is known that these tests exhibit more stochastic 364 characteristics. At low concentrations of pathogen nucleic acid, chance can dictate whether target 365 nucleic acid is captured in a pipet, bound during the extraction phase, efficiently eluted, or pipetted into 366 the final reaction mixture. All of this complexity is combined to determine the probability of detection at 367 and below the assay LoD. These data demonstrate how variations in characteristics of the underlying 368 test population should be considered when considering the static nature or dynamic nature of test 369 performance. 370 371 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. normalized to %-LOD as described in methods. The %-Detected at each relative concentration was 465 calculated, plotted, and subjected to non-linear regression with an exponential plateau function with Y0 466 = 0 and YM = 100%. Best fit line (solid line) and 95% confidence intervals (dashed lines) are shown. 467 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 

Assays: Superior Analytical Sensitivity of cobas SARS-CoV-2 Relative to NxTAG Cov Extended Panel and ID 410 NOW COVID-19 Test

Saliva as 415 an Alternate Specimen Source for Detection of SARS-CoV-2 in Symptomatic Patients Using Cepheid Xpert

Xpress SARS-CoV-2

Saliva or Nasopharyngeal Swab Specimens for 423 Detection of SARS-CoV-2

Multicenter Evaluation of the Cepheid Xpert Xpress SARS-CoV-2 Assay for the Detection of SARS-CoV-2 in 426

Statistics Notes: Bootstrap resampling methods

The Kolmogorov-Smirnov Test for Goodness of Fit

Evaluation of detection capability for clinical laboratory measurement procedures

Fuhrman 432 S, Antonara S. 2020. Clinical Evaluation and Utilization of Multiple Molecular In Vitro Diagnostic Assays for 433 the Detection of SARS-CoV-2

Nasal-Swab Testing Misses Patients with Low 435 SARS-CoV-2 Viral Loads. medRxiv

STARD 438 2015: an updated list of essential items for reporting diagnostic accuracy studies